Dr.ir. Jan Schrooten is co-founder and CEO of Antleron, a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. Antleron merges the potential of cells, biomaterials, biologics, 3D printing and bioreactors to accelerate the engineering of living therapies - empowering patients with fully personalized, regenerative care. Antleron translates these core technologies, using quality-by-design and artificial intelligence, into pioneering workflows that turn cells into living therapies. To support its mission, Antleron’s business philosophy is to create sustainable ventures that bring living, personalized therapies from idea to patient through risk & reward sharing partnerships. Jan Schrooten is board member of flanders.bio, the cluster organisation for the life sciences sector in Flanders.